Femasys issued U.S. patent covering FemBloc device
The Fly

Femasys issued U.S. patent covering FemBloc device

Femasys (FEMY) announces that the United States Patent and Trademark Office issued U.S. Patent No. 12,12796 covering FemBloc permanent birth control. This further strengthens Femasys’ intellectual property position and coverage for FemBloc, the Company’s leading therapeutic product candidate. The issued patent has an anticipated expiration in 2039 at the earliest. Femasys intends to continue to prosecute additional patent applications to further enhance its existing patent portfolio protecting FemBloc, along with the Company’s existing available therapeutic product, FemaSeed intratubal insemination for infertility treatment, and diagnostic products, FemVue, FemCath, FemCerv, and FemChec.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App